CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer

Civil Hospices of Lyon

Status: Enrolling

Conditions: Non-small Cell Lung Cancer

Treatments: Biological: Serum and plasma samples

Study type: Observational

Funder types: Other

Identifiers

NCT02764606

D50832

Details and patient eligibility

About

CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies

Enrollment: 250 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer
• age over 18 years
• patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years
• patient who signed the informed consent by the study protocol

Exclusion criteria were:

• any ongoing treatment for cancer
• any history of cancer within 5 years before the diagnosis of lung cancer
• any psychological, sociological or geographical conditions that would not allow the study follow-up

Trial design

250 participants in 1 patient group

Patients with a non-small cell lung cancer

Description:

Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).

Treatment:

Biological: Serum and plasma samples